MOMichael P. O'COnnell

Michael P. O'COnnell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael P. O'COnnell has a total of 201 co-authors. Here are the top co-authors by number of shared publications:

  • Amanda D. French

    Laboratory of Immunology and

    6 shared publications
  • Dennis D. Taub

    6 shared publications
  • Ashani T. Weeraratna

    Laboratory of Immunology, National Institute on Aging, National Institutes of Health, Baltimore, Maryland, USA

    5 shared publications
  • Fred E. Indig

    Authors' Affiliations: 1Tumor Metastasis and Microenvironment Program and 2Molecular and Cellular Oncogenesis Program, The Wistar Institute; 3Abramson Cancer Center, University of Pennsylvania, Philadelphia; 4Lehigh Valley Health Network, Allentown, Pennsylvania; 5The National Institute on Aging, NIH, Baltimore, Maryland; and 6Dana-Farber/Harvard Cancer Center, Boston, Massachusetts

    5 shared publications
  • Jennifer L. Fiori

    5 shared publications
  • Brittany P. Frank

    4 shared publications

Latest Publications

  • Open Access

    Anxiety and depression scores in maternity healthcare workers during the Covid‐19 pandemic

    by Gillian A. Corbett, Sarah J. Milne, Suruchi Mohan, Shuja Reagu, Tom Farrell, Stephen W. Lindow, Mark P. Hehir, Michael P. O’connell

    While Severe‐Acute‐Respiratory‐Syndrome‐CoronaVirus‐2 (SARSCoV‐2/Covid‐19) causes physical morbidity for healthcare workers (HCWs), Covid‐19 also carries psychological morbidity for HCWs. This morbidity translates to anxiety and depressive symptomatology. To this end, we assessed anxiety and depression among HCWs during Covid‐19 pandemic.


  • GATA-2–deficient mast cells limit IgE-mediated immediate hypersensitivity reactions in human subjects

    by Avanti Desai, Kathryn Sowerwine, Yihui Liu, Monica G. Lawrence, Jack Chovanec, Amy P. Hsu, Michael P. O'Connell, Jiwon Kim, Lisa Boris, Nina Jones, et al.


  • Top Cited Papers

    Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number

    by Jonathan J Lyons, Xiaomin Yu, Jason D Hughes, Quang T Le, Ali Jamil, Yun Bai, Nancy Ho, Ming Zhao, Yihui Liu, Michael P O'Connell, et al.

    Joshua Milner and colleagues show that increased TPSAB1 copy number causes a multisystem disorder marked by elevated basal serum tryptase levels. Shared symptoms in affected individuals include irritable bowel syndrome, cutaneous flushing and pruritus, connective tissue abnormalities and dysautonomia. Elevated basal serum tryptase levels are present in 4–6% of the general population, but the cause and relevance of such increases are unknown1,2. Previously, we described subjects with dominantly inherited elevated basal serum tryptase levels associated with multisystem complaints including cutaneous flushing and pruritus, dysautonomia, functional gastrointestinal symptoms, chronic pain, and connective tissue abnormalities, including joint hypermobility. Here we report the identification of germline duplications and triplications in the TPSAB1 gene encoding α-tryptase that segregate with inherited increases in basal serum tryptase levels in 35 families presenting with associated multisystem complaints. Individuals harboring alleles encoding three copies of α-tryptase had higher basal serum levels of tryptase and were more symptomatic than those with alleles encoding two copies, suggesting a gene-dose effect. Further, we found in two additional cohorts (172 individuals) that elevated basal serum tryptase levels were exclusively associated with duplication of α-tryptase–encoding sequence in TPSAB1, and affected individuals reported symptom complexes seen in our initial familial cohort. Thus, our findings link duplications in TPSAB1 with irritable bowel syndrome, cutaneous complaints, connective tissue abnormalities, and dysautonomia.


  • Diminution of signal transducer and activator of transcription 3 signaling inhibits vascular permeability and anaphylaxis

    by Valerie Hox, Michael P. O'COnnell, Jonathan J. Lyons, Paul Sackstein, Thomas Dimaggio, Nina Jones, Celeste Nelson, Manfred Boehm, Steven M. Holland, Alexandra F. Freeman, et al.


  • Wnt5A promotes an adaptive, senescent‐like stress response, while continuing to drive invasion in melanoma cells

    by Marie R. Webster, Mai Xu, Kathryn A. Kinzler, Amanpreet Kaur, Jessica Appleton, Michael P. O'COnnell, Katie Marchbank, Alexander Valiga, Vanessa M. Dang, Michela Perego, et al.

    We have previously shown that Wnt5A drives invasion in melanoma. We have also shown that Wnt5A promotes resistance to therapy designed to target the BRAFV600E mutation in melanoma. Here, we show that melanomas characterized by high levels of Wnt5A respond to therapeutic stress by increasing p21 and expressing classical markers of senescence, including positivity for senescence‐associated β‐galactosidase (SA‐β‐gal), senescence‐associated heterochromatic foci (SAHF), H3K9Me chromatin marks, and PML bodies. We find that despite this, these cells retain their ability to migrate and invade. Further, despite the expression of classic markers of senescence such as SA‐β‐gal and SAHF, these Wnt5A‐high cells are able to colonize the lungs in in vivo tail vein colony‐forming assays. This clearly underscores the fact that these markers do not indicate true senescence in these cells, but instead an adaptive stress response that allows the cells to evade therapy and invade. Notably, silencing Wnt5A reduces expression of these markers and decreases invasiveness. The combined data point to Wnt5A as a master regulator of an adaptive stress response in melanoma, which may contribute to therapy resistance.


  • Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2

    by Michael P. O'COnnell, Katie Marchbank, Marie R. Webster, Alexander A. Valiga, Amanpreet Kaur, Adina Vultur, Ling Li, Meenhard Herlyn, Jessie Villanueva, Qin Liu, et al.

    An emerging concept in melanoma biology is that of dynamic, adaptive phenotype switching, where cells switch from a highly proliferative, poorly invasive phenotype to a highly invasive, less proliferative one. This switch may hold significant implications not just for metastasis, but also for therapy resistance. We demonstrate that phenotype switching and subsequent resistance can be guided by changes in expression of receptors involved in the noncanonical Wnt5A signaling pathway, ROR1 and ROR2. ROR1 and ROR2 are inversely expressed in melanomas and negatively regulate each other. Furthermore, hypoxia initiates a shift of ROR1-positive melanomas to a more invasive, ROR2-positive phenotype. Notably, this receptor switch induces a 10-fold decrease in sensitivity to BRAF inhibitors. In patients with melanoma treated with the BRAF inhibitor vemurafenib, Wnt5A expression correlates with clinical response and therapy resistance. These data highlight the fact that mechanisms that guide metastatic progression may be linked to those that mediate therapy resistance. Significance: These data show for the first time that a single signaling pathway, the Wnt signaling pathway, can effectively guide the phenotypic plasticity of tumor cells, when primed to do so by a hypoxic microenvironment. Importantly, this increased Wnt5A signaling can give rise to a subpopulation of highly invasive cells that are intrinsically less sensitive to novel therapies for melanoma, and targeting the Wnt5A/ROR2 axis could improve the efficacy and duration of response for patients with melanoma on vemurafenib. Cancer Discov; 3(12); 1378–93. ©2013 AACR. This article is highlighted in the In This Issue feature, p. 1317


  • Open Access

    Lack of Wnt5A Expression in Merkel Cell Carcinoma

    by Ashani T. Weeraratna, Roland Houben, Michael P. O’connell, Jürgen C. Becker

    Merkel cell cancer (MCC) is a rare skin cancer of neuroendocrine origin, the onset of which can be induced by chronic sun exposure.1 The molecular mechanisms underlying the development and progression of MCC are unclear. Recently, it has been shown that the Merkel cell polyomavirus (MCV) is causally linked to MCC. The DNA of MCV can be detected in approximately 80% of MCCs and has been demonstrated to be monoclonally integrated into the genome of the tumor cells that express the MCV large T antigen.2


  • Open Access

    Heparan Sulfate Proteoglycan Modulation of Wnt5A Signal Transduction in Metastatic Melanoma Cells

    by Michael P. O'COnnell, Jennifer L. Fiori, Emily K. Kershner, Brittany P. Frank, Fred E. Indig, Dennis D. Taub, Keith S. Hoek, Ashani T. Weeraratna


  • Activation of Wnt5A signaling is required for CXC chemokine ligand 12–mediated T-cell migration

    by Manik C. Ghosh, Gary D. Collins, Bolormaa Vandanmagsar, Kalpesh Patel, Margaret Brill, Arnell Carter, Ana Lustig, Kevin G. Becker, William W. Wood, Chineye D. Emeche, et al.

    Chemokines mediate the signaling and migration of T cells, but little is known about the transcriptional events involved therein. Microarray analysis of CXC chemokine ligand (CXCL) 12−treated T cells revealed that Wnt ligands are significantly up-regulated during CXCL12 treatment. Real-time polymerase chain reaction and Western blot analysis confirmed that the expression of noncanonical Wnt pathway members (eg, Wnt5A) was specifically up-regulated during CXCL12 stimulation, whereas β-catenin and canonical Wnt family members were selectively down-regulated. Wnt5A augmented signaling through the CXCL12-CXCR4 axis via the activation of protein kinase C. Moreover, Wnt5A expression was required for CXCL12–mediated T-cell migration, and rWnt5A sensitized human T cells to CXCL12-induced migration. Furthermore, Wnt5A expression was also required for the sustained expression of CXCR4. These results were further supported in vivo using EL4 thymoma metastasis as a model of T-cell migration. Together, these data demonstrate that Wnt5A is a critical mediator of CXCL12-CXCR4 signaling and migration in human and murine T cells.